

# David A Power

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9088045/publications.pdf>

Version: 2024-02-01

87  
papers

5,412  
citations

81900

39  
h-index

79698

73  
g-index

87  
all docs

87  
docs citations

87  
times ranked

7228  
citing authors

#	ARTICLE	IF	CITATIONS
1	AMP-activated protein kinase phosphorylation of endothelial NO synthase. <i>FEBS Letters</i> , 1999, 443, 285-289.	2.8	729
2	Coordinated Control of Endothelial Nitric-oxide Synthase Phosphorylation by Protein Kinase C and the cAMP-dependent Protein Kinase. <i>Journal of Biological Chemistry</i> , 2001, 276, 17625-17628.	3.4	484
3	Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. <i>Journal of Molecular and Cellular Cardiology</i> , 2007, 42, 271-279.	1.9	453
4	Unrecognized Anemia in Patients With Diabetes. <i>Diabetes Care</i> , 2003, 26, 1164-1169.	8.6	291
5	Array-Based Gene Discovery with Three Unrelated Subjects Shows SCARB2/LIMP-2 Deficiency Causes Myoclonus Epilepsy and Glomerulosclerosis. <i>American Journal of Human Genetics</i> , 2008, 82, 673-684.	6.2	230
6	Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells. <i>Nature</i> , 2017, 545, 243-247.	27.8	181
7	Renal Structure in Normoalbuminuric and Albuminuric Patients With Type 2 Diabetes and Impaired Renal Function. <i>Diabetes Care</i> , 2013, 36, 3620-3626.	8.6	178
8	Role of the energy sensor AMP-activated protein kinase in renal physiology and disease. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 298, F1067-F1077.	2.7	126
9	Is Nonalbuminuric Renal Insufficiency in Type 2 Diabetes Related to an Increase in Intrarenal Vascular Disease?. <i>Diabetes Care</i> , 2006, 29, 1560-1566.	8.6	124
10	Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. <i>Medical Journal of Australia</i> , 2007, 186, 454-457.	1.7	119
11	NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy. <i>Diabetes</i> , 2017, 66, 2691-2703.	0.6	119
12	AMP-activated protein kinase isoenzyme family: subunit structure and chromosomal location. <i>FEBS Letters</i> , 1997, 409, 452-456.	2.8	112
13	Vascular endothelial growth factor is a survival factor for renal tubular epithelial cells. <i>American Journal of Physiology - Renal Physiology</i> , 2000, 278, F905-F915.	2.7	106
14	Phosphorylation of Acetyl-CoA Carboxylase by AMPK Reduces Renal Fibrosis and Is Essential for the Anti-Fibrotic Effect of Metformin. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2326-2336.	6.1	93
15	Heparanase Is Involved in the Pathogenesis of Proteinuria as a Result of Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 68-78.	6.1	86
16	Regulation of the renal-specific Na <sup>+</sup> K <sup>+</sup> 2Cl <sup>-</sup> co-transporter NKCC2 by AMP-activated protein kinase (AMPK). <i>Biochemical Journal</i> , 2007, 405, 85-93.	3.7	83
17	Diagnostic application of kidney allograft-derived absolute cell-free DNA levels during transplant dysfunction. <i>American Journal of Transplantation</i> , 2019, 19, 1037-1049.	4.7	71
18	Human Factor H-related Protein 5 (FHR-5). <i>Journal of Biological Chemistry</i> , 2001, 276, 6747-6754.	3.4	67

#	ARTICLE	IF	CITATIONS
19	Vision-Threatening Retinal Abnormalities in Chronic Kidney Disease Stages 3 to 5. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1866-1871.	4.5	65
20	Regulation of the energy sensor AMP-activated protein kinase in the kidney by dietary salt intake and osmolality. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 288, F578-F586.	2.7	63
21	Increased expression of heparanase in puromycin aminonucleoside nephrosis. <i>Kidney International</i> , 2001, 60, 1287-1296.	5.2	61
22	Acute renal ischemia rapidly activates the energy sensor AMPK but does not increase phosphorylation of eNOS-Ser <sup>1177</sup> . <i>American Journal of Physiology - Renal Physiology</i> , 2005, 289, F1103-F1115.	2.7	61
23	AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. <i>Kidney International</i> , 2014, 85, 191-197.	5.2	60
24	A Synthetic Heparanase Inhibitor Reduces Proteinuria in Passive Heymann Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 2882-2892.	6.1	58
25	Adhesion molecule interactions in human glomerulonephritis: Importance of the tubulointerstitium. <i>Kidney International</i> , 1996, 49, 127-134.	5.2	56
26	Redistribution of cytoplasmic VEGF to the basolateral aspect of renal tubular cells in ischemia-reperfusion injury. <i>Kidney International</i> , 2000, 57, 2445-2456.	5.2	56
27	Induction of Passive Heymann Nephritis in Complement Component 6-Deficient PVG Rats. <i>Journal of Immunology</i> , 2007, 179, 172-178.	0.8	55
28	Obesity-Related Chronic Kidney Disease—The Role of Lipid Metabolism. <i>Metabolites</i> , 2015, 5, 720-732.	2.9	52
29	5-aminimidazole-4-carboxamide ribonucleoside and AMP-activated protein kinase inhibit signalling through NF- $\kappa$ B. <i>Immunology and Cell Biology</i> , 2010, 88, 754-760.	2.3	50
30	Renal ischemia-reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expression. <i>Kidney International</i> , 2002, 61, 1696-1706.	5.2	49
31	Activation of nuclear factor- $\kappa$ B by podocytes in the autologous phase of passive Heymann nephritis. <i>Kidney International</i> , 2001, 59, 923-931.	5.2	48
32	Complement C5a Induces Renal Injury in Diabetic Kidney Disease by Disrupting Mitochondrial Metabolic Agility. <i>Diabetes</i> , 2020, 69, 83-98.	0.6	48
33	Lowering of Proteinuria in Response to Antihypertensive Therapy Predicts Improved Renal Function in Late but Not in Early Diabetic Nephropathy: A Pooled Analysis. <i>American Journal of Nephrology</i> , 2008, 28, 614-627.	3.1	47
34	Deficiency in Apoptosis-Inducing Factor Recapitulates Chronic Kidney Disease via Aberrant Mitochondrial Homeostasis. <i>Diabetes</i> , 2016, 65, 1085-1098.	0.6	47
35	Bradykinin stimulates endothelial cell fatty acid oxidation by CaMKK-dependent activation of AMPK. <i>Atherosclerosis</i> , 2008, 200, 28-36.	0.8	45
36	Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease. <i>Nephrology</i> , 2005, 10, 167-173.	1.6	44

#	ARTICLE	IF	CITATIONS
37	Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1611-1617.	0.7	44
38	Elevation of albumin synthesis rates in nephrotic patients measured with [1-13C]leucine. <i>Kidney International</i> , 1992, 41, 132-138.	5.2	40
39	CD44 in glomerulonephritis: Expression in human renal biopsies, the Thy 1.1 model, and by cultured mesangial cells. <i>Kidney International</i> , 1996, 50, 272-281.	5.2	39
40	Importance of the tubulointerstitium in human glomerulonephritis. II. Distribution of integrin chains $\beta$ 1, $\beta$ 1 to 6 and $\beta$ 5. <i>Kidney International</i> , 1997, 52, 103-110.	5.2	39
41	HB-EGF is produced in the peritoneal cavity and enhances mesothelial cell adhesion and migration. <i>Kidney International</i> , 2001, 59, 614-624.	5.2	39
42	Renal ageing: Changes in the cellular mechanism of energy metabolism and oxidant handling (Review) <i>Trends in Biochemical Sciences</i> , 2000, 25, 10-16.	1.6	36
43	Pre-eclampsia is associated with altered expression of the renal sodium transporters NKCC2, NCC and ENaC in urinary extracellular vesicles. <i>PLoS ONE</i> , 2018, 13, e0204514.	2.5	31
44	Heparin-binding epidermal growth factor-like growth factor in experimental models of membranous and minimal change nephropathy. <i>Kidney International</i> , 1998, 53, 1162-1171.	5.2	29
45	New insights into the molecular biology of the glomerular filtration barrier and associated disease. Review Article. <i>Nephrology</i> , 2005, 10, 157-166.	1.6	29
46	Novel mechanisms of Na <sup>+</sup> retention in obesity: phosphorylation of NKCC2 and regulation of SPAK/OSR1 by AMPK. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, F96-F106.	2.7	28
47	The Outcome of Renal Ischemia-Reperfusion Injury Is Unchanged in AMPK- $\beta$ 1 Deficient Mice. <i>PLoS ONE</i> , 2012, 7, e29887.	2.5	27
48	Diagnostic value of urinary N-acetyl- $\beta$ -D-glucosaminidase, its isoenzymes and the fractional excretion of sodium following renal transplantation. <i>Clinica Chimica Acta</i> , 1983, 130, 369-376.	1.1	25
49	Heparin-binding epidermal growth factor-like growth factor is expressed in the adhesive lesions of experimental focal glomerular sclerosis. <i>Kidney International</i> , 1999, 55, 2310-2321.	5.2	23
50	Phosphorylation of Neuronal and Endothelial Nitric Oxide Synthase in the Kidney with High and Low Salt Diets. <i>Nephron Physiology</i> , 2006, 102, p36-p50.	1.2	22
51	Activators of the energy sensing kinase AMPK inhibit random cell movement and chemotaxis in U937 cells. <i>Immunology and Cell Biology</i> , 2006, 84, 6-12.	2.3	21
52	Use of Copy Number Deletion Polymorphisms to Assess DNA Chimerism. <i>Clinical Chemistry</i> , 2014, 60, 1105-1114.	3.2	20
53	Monoclonal antibodies to cultured human glomerular mesangial cells. I. Reactivity with haematopoietic cells and normal kidney sections. <i>Journal of Pathology</i> , 1991, 163, 265-272.	4.5	19
54	Implementation of renal key performance indicators: Promoting improved clinical practice. <i>Nephrology</i> , 2015, 20, 184-193.	1.6	19

#	ARTICLE	IF	CITATIONS
55	Urokinase-plasminogen activator is synthesized in vitro by human glomerular epithelial cells but not by mesangial cells. <i>Kidney International</i> , 1994, 45, 43-47.	5.2	18
56	AMPK couples plasma renin to cellular metabolism by phosphorylation of ACC1. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, F679-F690.	2.7	18
57	Membranous glomerulonephritis associated with hepatitis C virus infection in an adolescent. <i>Pathology</i> , 1994, 26, 399-402.	0.6	17
58	A Study of VEGF and Its Receptors in Two Rat Models of Proteinuria. <i>Nephron Physiology</i> , 2004, 96, p26-p36.	1.2	16
59	Mutation of regulatory phosphorylation sites in PFKFB2 worsens renal fibrosis. <i>Scientific Reports</i> , 2020, 10, 14531.	3.3	16
60	Inhibition with Antisense Oligonucleotide Suggests that I $\kappa$ B- $\beta$ Does Not Form a Negative Autoregulatory Loop for NF- $\kappa$ B in Mesangial Cells. <i>Nephron Experimental Nephrology</i> , 2000, 8, 144-151.	2.2	15
61	Balancing the energy equation for healthy kidneys. <i>Journal of Pathology</i> , 2015, 237, 407-410.	4.5	14
62	Independent of Renox, NOX5 Promotes Renal Inflammation and Fibrosis in Diabetes by Activating ROS-Sensitive Pathways. <i>Diabetes</i> , 2022, 71, 1282-1298.	0.6	14
63	Low salt concentrations activate AMP-activated protein kinase in mouse macula densa cells. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, F801-F809.	2.7	13
64	Inhibition of heparin-binding epidermal growth factor-like growth factor increases albuminuria in puromycin aminonucleoside nephrosis. <i>Kidney International</i> , 2000, 58, 1098-1107.	5.2	12
65	An immunohistological study of epidermal growth factor receptor and neu receptor expression in proliferative glomerulonephritis. <i>Pathology</i> , 1993, 25, 327-332.	0.6	11
66	Transcription factor NF- $\kappa$ B in glomerulonephritis. <i>Nephrology</i> , 2000, 5, 71-82.	1.6	10
67	Predictors of Early Dialysis Vascular-Access Failure after Thrombolysis. <i>American Journal of Nephrology</i> , 2008, 28, 181-189.	3.1	10
68	Activation of AMPK reduces the co-transporter activity of NKCC1. <i>Molecular Membrane Biology</i> , 2014, 31, 95-102.	2.0	10
69	Abnormal Processing of Autophagosomes in Transformed B Lymphocytes from SCARB2-Deficient Subjects. <i>BioResearch Open Access</i> , 2013, 2, 40-46.	2.6	9
70	The Thiazide-Sensitive Co-Transporter Promotes the Development of Sodium Retention in Mice with Diet-Induced Obesity. <i>Kidney and Blood Pressure Research</i> , 2015, 40, 509-519.	2.0	9
71	TUBULOINTERSTITIAL NEPHRITIS FOLLOWING HIGH-DOSE IFOSFAMIDE IN THREE BREAST CANCER PATIENTS. <i>Pathology</i> , 2000, 32, 166-170.	0.6	9
72	Introduction of Renal Key Performance Indicators Associated with Increased Uptake of Peritoneal Dialysis in a Publicly Funded Health Service. <i>Peritoneal Dialysis International</i> , 2017, 37, 198-204.	2.3	7

#	ARTICLE	IF	CITATIONS
73	EVIDENCE THAT PROTECTIVE Fc-RECEPTOR-BLOCKING ANTIBODIES IN RENAL TRANSPLANTATION ARE ALLOANTIBODIES NOT AUTOANTIBODIES. <i>Transplantation</i> , 1985, 39, 520-522.	1.0	6
74	Corticosteroids Worsen Proteinuria and Increase Intraglomerular Signaling by NF- $\kappa$ B in a Model of Membranous Glomerulonephritis. <i>Nephron Experimental Nephrology</i> , 2010, 116, e23-e31.	2.2	6
75	Biological Drugs and the Coming of Biosimilars. <i>Journal of Pharmacy Practice and Research</i> , 2008, 38, 137-139.	0.8	5
76	Three Dimensional Glomerular Reconstruction: A Novel Approach to Evaluate Renal Microanatomy in Diabetic Kidney Disease. <i>Scientific Reports</i> , 2019, 9, 1829.	3.3	4
77	Blocking AMPK signalling to acetyl-CoA carboxylase increases cisplatin-induced acute kidney injury and suppresses the benefit of metformin. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113377.	5.6	4
78	A Human Lymphocytotoxic Autoantibody Is Encoded By Antibody Variable Region Genes In Their Germ Line Configuration. <i>Transplantation</i> , 1993, 56, 1236-1241.	1.0	3
79	Non-Cytotoxic Alloantibodies Defined by the EA Rosette Inhibition Assay. <i>International Archives of Allergy and Immunology</i> , 1984, 74, 324-331.	2.1	2
80	THE EFFECT OF CYCLOSPORINE ON HUMORAL AND CELLULAR ALLOREACTIVITY TO ALLOGENEIC PREGNANCY IN RATS. <i>Transplantation</i> , 1986, 42, 400-402.	1.0	2
81	Absence of the $\beta$ 1 subunit of AMP-activated protein kinase reduces myofibroblast infiltration of the kidneys in early diabetes. <i>International Journal of Experimental Pathology</i> , 2019, 100, 114-122.	1.3	2
82	Serum potassium abnormalities in chronic kidney disease: prevalence, patient characteristics and clinical outcomes. <i>Internal Medicine Journal</i> , 2021, 51, 1906-1918.	0.8	2
83	Abnormal Renal Function and Electrolyte Disturbances in Older People. <i>Journal of Pharmacy Practice and Research</i> , 2009, 39, 230-234.	0.8	1
84	Establishing a Normal Baseline for Immunohistochemical Studies of the Kidney. <i>Nephron</i> , 1992, 62, 479-479.	1.8	0
85	Malignant Hypertension Causing a Pulmonary-Renal Syndrome. <i>Case Reports in Nephrology</i> , 2018, 2018, 1-4.	0.4	0
86	Dialysis and driving: an anonymous survey of patients receiving dialysis for end-stage kidney disease. <i>Internal Medicine Journal</i> , 2021, 51, 1691-1699.	0.8	0
87	485-P: T Lymphocytes Infiltration in Kidneys of People with Type 2 Diabetes. <i>Diabetes</i> , 2020, 69, 485-P.	0.6	0